Compare Summit Therapeutics Inc (SMMT) vs Trade Desk Inc (TTD) Price & Performance

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.

The Trade Desk (TTD) trades at $12.34, up 2.07% today but remains down significantly from recent highs. Technical indicators show a bearish trend with mixed momentum signals. Fundamentally, the company maintains strong profitability with 76.87% gross margins and 15.44% ROE, though revenue growth has slowed to 3% in 2026. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions and slower CTV growth.

Investment outlook remains cautious with analyst consensus at $14.72 target price representing 19% upside potential. Key opportunities include TTD's dominant position in programmatic advertising and healthy cash flow generation. Primary risks involve intensifying competition from tech giants, slowing revenue growth, and execution challenges during restructuring. The stock presents a value opportunity for patient investors if competitive pressures ease.